Zelira Therapeutics Limited

ASX:ZLD Rapporto sulle azioni

Cap. di mercato: AU$8.1m

Zelira Therapeutics Performance dei guadagni passati

Il passato criteri di controllo 0/6

Zelira Therapeutics's earnings have been declining at an average annual rate of -41.7%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been declining at an average rate of 3.5% per year.

Informazioni chiave

-41.7%

Tasso di crescita degli utili

-20.6%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore31.2%
Tasso di crescita dei ricavi-3.5%
Rendimento del capitale proprion/a
Margine netto-38,513.0%
Ultimo aggiornamento sui guadagni30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Zelira Therapeutics Limited's (ASX:ZLD) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 08
Zelira Therapeutics Limited's (ASX:ZLD) CEO Will Probably Find It Hard To See A Huge Raise This Year

Is Zelira Therapeutics (ASX:ZLD) In A Good Position To Invest In Growth?

Jul 14
Is Zelira Therapeutics (ASX:ZLD) In A Good Position To Invest In Growth?

Here's Why Zelira Therapeutics (ASX:ZLD) Must Use Its Cash Wisely

Jan 19
Here's Why Zelira Therapeutics (ASX:ZLD) Must Use Its Cash Wisely

Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

Sep 25
Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

Jun 03
Will Zelira Therapeutics (ASX:ZLD) Spend Its Cash Wisely?

A Quick Analysis On Zelira Therapeutics' (ASX:ZLD) CEO Compensation

Dec 31
A Quick Analysis On Zelira Therapeutics' (ASX:ZLD) CEO Compensation

Ripartizione dei ricavi e delle spese

Come Zelira Therapeutics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

ASX:ZLD Ricavi, spese e utili (AUD Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Jun 240-3723
31 Mar 240-3632
31 Dec 230-3641
30 Sep 230-2141
30 Jun 230-651
31 Mar 231-882
31 Dec 221-10102
30 Sep 221-11112
30 Jun 222-12121
31 Mar 221-11101
31 Dec 211-1081
30 Sep 211-982
30 Jun 211-972
31 Mar 210-863
31 Dec 200-854
30 Sep 200-854
30 Jun 200-744
31 Mar 200-633
31 Dec 191-433
30 Sep 191-423
30 Jun 191-422
31 Mar 191-312
31 Dec 180-312
30 Sep 180-312
30 Jun 180-212
31 Mar 180-212
31 Dec 170-211
30 Sep 170-411
30 Jun 170-621
31 Dec 160-520
30 Jun 160000

Guadagni di qualità: ZLD is currently unprofitable.

Margine di profitto in crescita: ZLD is currently unprofitable.


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: ZLD is unprofitable, and losses have increased over the past 5 years at a rate of 41.7% per year.

Accelerare la crescita: Unable to compare ZLD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Guadagni vs Settore: ZLD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (46.5%).


Rendimento del capitale proprio

ROE elevato: ZLD's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate